Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEWARK, CA / ACCESS NEWSWIRE / SEPTEMBER 8, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED A SHARE REPURCHASE PROGRAM UNDER WHICH THE COMPANY MAY REPURCHASE UP TO $300 MILLION OF ITS OUTSTANDING COMMON STOCK. THE COMPANY INTENDS TO FUND THE SHARE REPURCHASES FROM ITS CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES, AND FROM ROYALTIES AND OTHER PAYMENTS RECEIVED UNDER THE COMPANY'S COLLABORATION ARRANGEMENTS WITH TAKEDA RELATED TO MIMRYLOTM (RUSFERTIDE) AND WITH JOHNSON & JOHNSON RELATED TO ICOTYDETM (ICOTROKINRA).

PROTAGONIST THERAPEUTICS ANNOUNCES $300 MILLION SHARE REPURCHASE PROGRAM

NEWARK, CA / ACCESS NEWSWIRE / SEPTEMBER 2, 2026 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY ANNOUNCED THAT DINESH V. PATEL, PH.D.

PROTAGONIST THERAPEUTICS TO PARTICIPATE IN TWO INVESTMENT BANK CONFERENCES IN SEPTEMBER 2026

MIMRYLO IS THE FIRST AND ONLY HEPCIDIN MIMETIC PEPTIDE THERAPY APPROVED FOR THE TREATMENT OF ERYTHROCYTOSIS IN ADULTS WITH POLYCYTHEMIA VERA, OFFERING A NOVEL MECHANISM TO MAINTAIN HEMATOCRIT CONTROL, MEANINGFULLY REDUCE PHLEBOTOMY BURDEN, AND IMPROVE FATIGUE APPROVAL SUPPORTED BY PHASE 3 VERIFY RESULTS SHOWING 76.9% OF PATIENTS ACHIEVED RESPONSE DURING WEEKS 20-32 FDA APPROVAL TRIGGERS $275M IN MILESTONES, 14%-29% ROYALTIES, WITH UP TO AN ADDITIONAL $875M IN POTENTIAL FUTURE MILESTONES INVESTOR CALL TO BE HELD MONDAY, AUGUST 31ST AT 8:30 AM ET NEWARK, CA / ACCESS NEWSWIRE / AUGUST 28, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") ANNOUNCED TODAY THAT TAKEDA RECEIVED U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR MIMRYLO (RUSFERTIDE), A SUBCUTANEOUSLY DELIVERED FIRST-IN-CLASS HEPCIDIN MIMETIC PEPTIDE FOR THE TREATMENT OF ERYTHROCYTOSIS IN ADULTS WITH POLYCYTHEMIA VERA (PV). MIMRYLO IS THE FIRST AND ONLY HEPCIDIN MIMETIC APPROVED FOR POLYCYTHEMIA VERA (PV), A BLOOD CANCER CHARACTERIZED BY EXCESSIVE PRODUCTION OF RED BLOOD CELLS.

PROTAGONIST THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF HEPCIDIN MIMETIC PEPTIDE MIMRYLO(TM) (RUSFERTIDE) FOR POLYCYTHEMIA VERA

NEWARK, CA / ACCESS NEWSWIRE / AUGUST 18, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON AUGUST 17, 2026, IT GRANTED INDUCEMENT AWARDS TO TWO RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

PROTAGONIST THERAPEUTICS REPORTS GRANTING OF INDUCEMENT AWARDS

ICOTYDE FIRST FULL QUARTER OF COMMERCIAL SALES WITH STRONG EARLY ADOPTION RUSFERTIDE NDA UNDER PRIORITY REVIEW FOR POLYCYTHEMIA VERA; PDUFA DATE IN AUGUST 2026 COMPREHENSIVE PHASE 2B PROGRAM WITH PN-881, AN ORAL IL-17 ANTAGONIST FOR PSORIASIS, PLANNED TO INITIATE EARLY Q1 2027 PHASE 1 STUDY INITIATED WITH PN-477SC, A TRIPLE GLP1/GIP/GCG AGONIST PEPTIDE FOR OBESITY CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $849.5 MILLION AS OF JUNE 30, 2026 NEWARK, CA / ACCESS NEWSWIRE / AUGUST 5, 2026 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026 AND PROVIDED A CORPORATE UPDATE. "THE SECOND QUARTER OF 2026 MARKED A DEFINING GROWTH PHASE FOR PROTAGONIST WITH A SUCCESSFUL COMMERCIAL LAUNCH OF ICOTYDE THROUGH OUR STRATEGIC PARTNER AND ACCELERATING MOMENTUM ACROSS OUR INTERNAL R&D PIPELINE.

PROTAGONIST REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEWARK, CA / ACCESS NEWSWIRE / AUGUST 4, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON JULY 31, 2026, IT GRANTED INDUCEMENT AWARDS TO TWO RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

NEWARK, CA / ACCESS NEWSWIRE / JULY 16, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON JULY 15, 2026, IT GRANTED INDUCEMENT AWARDS TO THREE RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

NEWARK, CA / ACCESS NEWSWIRE / JULY 1, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON JUNE 30, 2026, IT GRANTED INDUCEMENT AWARDS TO THREE RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

NEWARK, CA / ACCESS NEWSWIRE / JUNE 16, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON JUNE 15, 2026, IT GRANTED INDUCEMENT AWARDS TO THREE RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

NEWARK, CA / ACCESS NEWSWIRE / JUNE 1, 2026 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT FOUR ABSTRACTS HIGHLIGHTING RUSFERTIDE IN POLYCYTHEMIA VERA (PV) WILL BE PRESENTED AT THE 2026 EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS (EHA2026 CONGRESS), TAKING PLACE JUNE 11-14, 2026, IN STOCKHOLM, SWEDEN. THE PRESENTATIONS INCLUDE ANALYSES FROM THE RANDOMIZED, CONTROLLED PHASE 3 VERIFY STUDY, AS WELL AS LONG-TERM RESULTS FROM THE PHASE 2 REVIVE AND THRIVE OPEN-LABEL EXTENSION STUDIES.

Protagonist Therapeutics, Inc.

PTGX

Price

Financial Reports

No items found.

Press Releases

Protagonist Therapeutics, Inc.

PTGX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PTGX